Boston Business Journal: Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M

One of the researchers behind Merck's blockbuster cancer drug Keytruda has launched a new startup with the aim of expanding the drug industry's ability to leverage the immune system against cancer. Werewolf Therapeutics has emerged from stealth mode with $56 million from MPM Capital, the Longwood Fund and others.

Read the full story

Boston Business Journal

By Allison DeAngelis